
Stock Details
CEO
Cary John Claiborne MBA
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
5
Address
1180 Seminole Trail, Charlottesville, VA, 22901
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Top Competitors
Income Statement
Financials
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Adial Pharmaceuticals, Inc. $0.36
$0
$249.61
$325
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results